- Home
- ASTC vs IMNN Comparison
ASTC vs IMNN Comparison
Compare ASTC & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASTC | IMNN |
|---|---|---|
| Founded | 1984 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 12.9M |
| IPO Year | 1995 | 1985 |
Fundamental Metrics
Financial Performance| Metric | ASTC | IMNN |
|---|---|---|
| Price | $3.64 | $3.78 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $182.61 |
| AVG Volume (30 Days) | ★ 138.0K | 67.9K |
| Earning Date | 02-13-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,312,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.06 | N/A |
| 52 Week Low | $2.47 | $2.99 |
| 52 Week High | $8.01 | $41.22 |
Technical Indicators
Market Signals| Indicator | ASTC | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 43.79 | 49.02 |
| Support Level | $3.43 | $2.99 |
| Resistance Level | $3.88 | $4.00 |
| Average True Range (ATR) | 0.38 | 0.30 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 19.01 | 62.79 |
Price Performance
Historical ComparisonAbout ASTC Astrotech Corporation (DE)
Astrotech Corp is a science and technology development company. The firm invents, acquires, and commercializes technological innovations sourced from internal research, universities, laboratories, and research institutions. The 1st Detect develops, manufactures, and sells chemical analyzers for use in the airport security, military, and breath analysis markets. AgLAB develops a series of mass spectrometers for use in the agriculture market.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).